{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:39:57Z","timestamp":1772854797981,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/inf.0b013e31828693c5","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T13:14:04Z","timestamp":1359033244000},"page":"760-767","source":"Crossref","is-referenced-by-count":36,"title":["One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children"],"prefix":"10.1097","volume":"32","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal R.","family":"Lestrate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aftab","family":"Naz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Blatter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard R.","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-19-20210202","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"suppl 12","key":"R2-19-20210202","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy.","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R3-19-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-19-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jpids\/pir003","article-title":"The burden of infant meningococcal disease in the United States.","volume":"1","author":"Judelsohn","year":"2012","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R9-19-20210202","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"key":"R12-19-20210202","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"R13-19-20210202","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"R14-19-20210202","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"R15-19-20210202","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4161\/hv.20229","article-title":"Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.","volume":"8","author":"Knuf","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R16-19-20210202","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile.","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R17-19-20210202","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccin"},{"key":"R18-19-20210202","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R19-19-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"R20-19-20210202","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4161\/hv.20211","article-title":"The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.","volume":"8","author":"Dbaibo","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R21-19-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.20212","article-title":"The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.","volume":"8","author":"Aplasca-De Los Reyes","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R22-19-20210202","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R23-19-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R24-19-20210202","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10096-009-0848-8","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.","volume":"29","author":"Halperin","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R25-19-20210202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R26-19-20210202","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"R27-19-20210202","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection-serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R28-19-20210202","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/INF.0b013e3181cdd379","article-title":"Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.","volume":"29","author":"Marshall","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R29-19-20210202","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"R30-19-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents.","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"R31-19-20210202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"R32-19-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/02770903.2011.637594","article-title":"Asthma incidence among children and adults: findings from the Behavioral Risk Factor Surveillance system asthma call-back survey-United States, 2006-2008.","volume":"49","author":"Winer","year":"2012","journal-title":"J Asthma"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0b013e31828693c5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:09:30Z","timestamp":1620954570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201307000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31828693c5","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}